Chemomab Q2 net loss $6.2M, cash $51.8M; NASH topline due by year-end

Chemomab Therapeutics Ltd.

2022-Q2 EPS reported $0.05

Net loss $6.2M ($0.03/share) for Q2 2022 vs $2.8M loss in Q2 2021; R&D expense rose to $2.9M from $1.3M.
Cash, equivalents and deposits $51.8M at June 30; runway expected through end of 2023.
Phase 2 NASH trial completed treatment; topline safety and activity data expected before year-end 2022.
Phase 2 PSC trial expanded to 93 patients across three dose cohorts; topline data anticipated H2 2024.
Appointed Jill Quigley to board, Ilan Vaknin as VP R&D, and Christina Crater as VP Clinical Development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.